Project A Phase III, open-label, randomized Study of MPDL3280A (Anti-PD-L1 antibody) in combination with bevacizumab…

Basic data

Title:
A Phase III, open-label, randomized Study of MPDL3280A (Anti-PD-L1 antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma
Duration:
10/03/2016 to 09/03/2020
Abstract / short description:
A Phase III, open-label, randomized Study of MPDL3280A
(Anti-PD-L1 antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma
Keywords:
clinical trial
klinische Studie

Staff

Managers

Faculty of Medicine
University of Tübingen

Contact persons

Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Diagnostic and Interventional Radiology
Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine

Funders

Grenzach-Wyhlen, Baden-Württemberg, Germany
Help

will be deleted permanently. This cannot be undone.